We place equal emphasis on both API and preparation businesses, endogenous growth and extensive expansion; continuously consolidate the foundation of characteristic APIs, vigorously develop the preparation business, further improve the product line deployment in the field of anticoagulation, and become a leader in the niche therapeutic areas.

With the nuclide drugs as the new core competitiveness of the company, we will perfect the domestic nuclide drug network, and build up a platform for the entire value industry chain of the nuclide drug under the development ideas of “wading into the upstream, integrating the downstream and deploying the frontier”.

We will increase investment in R&D, enhance the strength in this aspect, focus on the development of innovative medicines for malignant tumors, neurodegenerative diseases and cardiovascular and cerebrovascular diseases, and introduce and develop the latest diagnostic and therapeutic nuclide drugs to fill in the gaps in China for the benefit of patients.